can glp-1 cause depression The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy Doctors and patients across social

Important safety considerations during the initial treatment period include: Monitoring for severe gastrointestinal symptoms: Persistent vomiting, severe abdominal pain, or signs of pancreatitis (severe upper abdominal pain radiating to the back) require immediate medical evaluation

Lower prices expand the patient pool

So far, Novo is furthest ahead in developing an obesity pill

I couldnt be Happier

Communicate your wellness program to employees Review the delivery of your benefits, and check that your employees understand how your wellness stipend works and the value it provides

Clinical trials demonstrate that semaglutide can produce approximately 15% body weight reduction over 68 weeks, while tirzepatide can achieve about 21% reduction over 72 weeks when combined with lifestyle modifications in people without diabetes